Results 51 to 60 of about 101,548 (353)

Distinct phosphorylation clusters determines the signalling outcome of the free fatty acid receptor FFA4/GPR120 [PDF]

, 2016
It is established that long-chain free fatty acids including ω-3 fatty acids mediate an array of biological responses through members of the free fatty acid receptor family, which includes FFA4.
Alvarez-Curto, Elisa, Butcher, Adrian J., Hudson, Brian D., Miller, Ashley M., Milligan, Graeme, Prihandoko, Rudi, Tobin, Andrew B., Ulven, Trond   +7 more
core   +2 more sources

The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy

Scientific Reports
This large community-based cohort study investigates the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Liraglutide and Semaglutide, on the risk of developing psychiatric conditions such as depression, anxiety, and suicidal
E. Kornelius, Jing-Yang Huang, S. Lo, Chien-Ning Huang, Yi-Sun Yang   +4 more
semanticscholar   +1 more source

Receptor activity modifying protein-directed G protein signaling specificity for the calcitonin gene-related peptide family of receptors [PDF]

, 2016
The calcitonin gene-related peptide (CGRP) family of G protein-coupled receptors (GPCRs) is formed through association of the calcitonin receptor-like receptor (CLR) and one of three receptor activitymodifying proteins (RAMPs).
Weston, Cathryn, Winfield, Ian, Harris, Matthew, Hodgson, Rose, Shah, Archna, Dowell, Simon J, Mobarec, Juan Carlos, Woodlock, David A, Reynolds, Christopher A, Poyner, David R, Watkins, Harriet A, Ladds, Graham   +11 more
core   +4 more sources

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use

Diabetes, obesity and metabolism, 2022
To explore the modifying effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use on outcomes with finerenone across a wide spectrum of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the pooled analysis of FIDELIO‐DKD and
P. Rossing, R. Agarwal, S. Anker, G. Filippatos, B. Pitt, L. Ruilope, V. Fonseca, G. Umpierrez, M. L. Caramori, A. Joseph, Marc Lambelet, R. Lawatscheck, G. Bakris   +12 more
semanticscholar   +1 more source

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists

Endocrinology and Metabolism, 2016
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade. The benefits of GLP-1 RAs are derived from their pleiotropic effects, which include glucose-dependent insulin secretion, suppressed glucagon secretion, and ...
Yu Mi Kang, Chang Hee Jung
openaire   +3 more sources

Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies

Journal of Diabetes Investigation, 2021
Aims/Introduction The prevalence and pathophysiological background of type 2 diabetes mellitus vary across ethnicities, and can affect treatment responses.
Fuqiang Liu, Yuan Liu, Minzhi Liu, Guangyu Wu, Minlu Zhang, Xia Zhang, Nan Cui, Huiqiu Yin, Li Chen   +8 more
doaj   +1 more source

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources

Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]

, 2015
AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo, Dagostino, Mariangela Pia, Fallarino, Mara, Filardi, Tiziana, Lenzi, Andrea, Mandosi, Elisabetta, Morano, Susanna, Nieddu, Luciano, Romagnoli, Elisabetta, Turinese, Irene   +9 more
core   +1 more source

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect

Cardiovascular Diabetology, 2021
Incretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
E. Fisman, A. Tenenbaum
semanticscholar   +1 more source

The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. [PDF]

, 2017
ObjectiveThe differential effect of GLP-1 agonist Exenatide on functional connectivity of the nucleus tractus solitaries (NTS), a key region associated with homeostasis, and on appetite-related behaviours was investigated in women with normal weight ...
Connolly, L, Coveleskie, K, Gupta, A, Kilpatrick, LA, Labus, JS, Mayer, EA, Sanmiguel, C, Stains, J   +7 more
core   +3 more sources